期刊
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
卷 58, 期 11, 页码 1095-1104出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2011.06.016
关键词
cardiac stem cell therapy; intracoronary; intramyocardial
资金
- German Ministry of Education and Research (BMBF) [FKZ 0312138A]
- State of Mecklenburg-Pomerania [FKZ V230-630-08-TFMV-F/S-035]
- German Research Foundation [SFB Transregio 37, TP A4, B2, B5]
Intracoronary and intramyocardial stem cell therapy aim at the repair of compromised myocardium thereby-as a causal treatment-preventing ventricular remodeling and improving overall performance. Since the first-inhuman use of bone marrow stem cells (BMCs) after acute myocardial infarction in 2001, a large number of clinical studies have demonstrated their clinical benefit: BMC therapy can be performed with usual cardiac catheterization techniques in the conscious patient as well as also easily during cardiosurgical interventions. New York Heart Association severity degree of patients as well as physical activity improve in addition to (on top of) all other therapeutic regimens. Stem cell therapy also represents an ultimate approach in advanced cardiac failure. For acute myocardial infarction and chronic ischemia, long-term mortality after 1 and 5 years, respectively, is significantly reduced. A few studies also indicate beneficial effects for chronic dilated cardiomyopathy. The clinical use of autologous BMC therapy implies no ethical problems, when unmodified primary cells are used. With the use of primary BMCs, there are no major stem cell-related side effects, especially no cardiac arrhythmias and inflammation. Various mechanisms of the stem cell action in the human heart are discussed, for example, cell transdifferentiation, cell fusion, activation of intrinsic cardiac stem cells, and cytokine-mediated effects. New techniques allow point-of-care cell preparations, for example, within the cardiac intervention or operation theater, thereby providing short preparation time, facilitated logistics of cell transport, and reasonable cost effectiveness of the whole procedure. The 3 main indications are acute infarction, chronic ischemic heart failure, and dilated cardiomyopathy. Future studies are desirable to further elucidate the mechanisms of stem cell action and to extend the current use of intracoronary and/or intramyocardial stem cell therapy by larger and presumably multicenter and randomized trials. (J Am Coll Cardiol 2011; 58: 1095-104) (C) 2011 by the American College of Cardiology Foundation
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据